New drug to help common bowel disease

(Medical Xpress)—An international team led by University of Adelaide researchers has identified the mechanism of pain relief of a new drug for treating Irritable Bowel Syndrome with Constipation (IBS-C), based on nonclinical studies, and quantified its effectiveness in pain relief in human trials.

Published in the journal Gastroenterology, the study describes the pain mechanism of action for Linaclotide, a recently approved drug for the treatment of and constipation in adult IBS-C patients.

IBS is a potentially debilitating condition with abdominal pain, bloating, diarrhoea and/or constipation. It affects up to 15% of western populations, costing millions of dollars annually in Australia alone in lost productivity and health care. Approximately one third of IBS patients are diagnosed as having IBS-C.

"This is a significant finding and very good news for IBS-C sufferers," says study leader Dr Stuart Brierley, NHMRC
RD Wright Biomedical Fellow in the University's Nerve-Gut Research Laboratory. "IBS affects many people, particularly women, on a daily basis and has a significant impact on their quality of life. Abdominal pain is often the most troubling symptom to IBS patients and has been the most difficult symptom to treat.

"The drug is effective in relieving abdominal pain associated with IBS-C and is already available and registered for use by IBS-C patients in the USA and Europe. It is yet to go through the regulatory process in Australia."

The research is a collaboration between the Nerve-Gut Research Laboratory, (University of Adelaide) and Ironwood Pharmaceuticals Inc, the developers of Linaclotide. Linaclotide is a new class of medicine and is the only treatment for IBS-C currently registered with the European Medicines Agency; it is also the first prescription treatment available in over six years for adults with IBS-C in the US.

Linaclotide binds the receptor domain of guanylate cyclase-C on the inner lining of the intestines. It is marketed by Ironwood and Forest Laboratories Inc as Linzess® in the US and by Ironwood and Almirall SA as Constella in Europe. Ironwood has partnerships through which it is conducting clinical trials of Linaclotide in China and Japan. Ironwood is exploring partnership opportunities for advancing Linaclotide in unpartnered territories, including Australia and New Zealand.

Dr Brierley, in the Nerve-Gut Research Laboratory, collaborated with Ironwood to further investigate how Linaclotide acts within the gastrointestinal tract to reduce abdominal pain. It had been shown to increase the secretion of fluids into the intestine and improve transit through the gastrointestinal tract. However, initial trials had shown that it also reduced abdominal pain associated with IBS-C, independently of its action on improving .

Pre-clinical studies by the Nerve-Gut Research Laboratory showed that Linaclotide inhibits pain nerve endings in the intestine through a novel physiological pathway localised to the . "The study also showed the analgesic effect translated into clinical findings in humans," says Dr Brierley. "IBS-C patients given the drug orally showed significant improvement in over those given placebo during a 26-week trial."

add to favorites email to friend print save as pdf

Related Stories

New IBS treatment shows potential in Phase 2 study

Aug 12, 2013

Patients with diarrhea-predominant irritable bowel syndrome, or IBS-D, treated with eluxadoline achieved better clinical response and experienced more symptom improvement than those using placebo, according to a recent study ...

New drug approved for irritable bowel, chronic constipation

Aug 30, 2012

(HealthDay)—Linzess (linaclotide) has been approved by the U.S. Food and Drug Administration to treat forms of chronic constipation that don't respond to traditional treatment, and irritable bowel syndrome accompanied by ...

Researcher: Hypnosis should be offered to patients with IBS

Dec 18, 2012

Hypnotherapy helps fight IBS symptoms. These are the findings of a thesis from Sahlgrenska Academy, University of Gothenburg, Sweden which proposes implementing this treatment method into the care of severe sufferers of this ...

Recommended for you

Dengue fever strikes models in Japan

1 hour ago

A worsening outbreak of dengue fever in Japan has claimed its first celebrities—two young models sent on assignment to the Tokyo park believed to be its source.

Japanese researchers develop 30-minute Ebola test

1 hour ago

Japanese researchers said Tuesday they had developed a new method to detect the presence of the Ebola virus in 30 minutes, with technology that could allow doctors to quickly diagnose infection.

Senegal monitors contacts of 1st Ebola patient

13 hours ago

Senegalese authorities on Monday were monitoring everyone who was in contact with a student infected with Ebola who crossed into the country, and who has lost three family members to the disease.

Cerebral palsy may be hereditary

19 hours ago

Cerebral palsy is a neurological developmental disorder which follows an injury to the immature brain before, during or after birth. The resulting condition affects the child's ability to move and in some ...

19 new dengue cases in Japan, linked to Tokyo park

Sep 01, 2014

Japan is urging local authorities to be on the lookout for further outbreaks of dengue fever, after confirming another 19 cases that were contracted at a popular local park in downtown Tokyo.

User comments